Epstein-Barr virus permissively infects human syncytiotrophoblasts in vitro and induces replication of human T cell leukemia-lymphoma virus type I in dually infected cells

Virology

Volumn 229, Issue 2, 1997, Pages 400-414

  Tóth, Ferenc D ^a,b   Aboagye Mathiesen, George ^a   Nemes, József ^b   Liu, Xiangdong ^a   Andirkó, István ^b   Hager, Henrik ^a   Zdravkovic, Milan ^a   Szabó, Judit ^b   Kiss, Jolán ^b   Aranyosi, János ^b   Ebbesen, Peter ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; IN VITRO STUDY; PLACENTA; PRIORITY JOURNAL; SYNCYTIOTROPHOBLAST; VERTICAL TRANSMISSION; VIRUS REPLICATION; VIRUS TRANSMISSION;

HTLV; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA LYMPHOMA VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 0031575803     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8449     Document Type: Article

References (74)

1. Birkenbach M., Tong X., Bradbury L. E., Tedder T. F., Kieff E. Characterization of an Epstein-Barr virus receptor on human epithelial cells. J. Exp. Med. 176:1992;1405-1414.
2. Clapham P., Nagy K., Cheingsong-Popov R., Exley M., Weiss R. A. Productive infection and cell-free transmission of human T-cell leukemia virus in a nonlymphoid cell line. Science. 222:1983;1125-1127.
3. Cohen G. H., Dietzschold B., Ponce de Leon M., Long D., Golub A., Varrichio A., Pereira L., Eisenberg R. J. Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody. J. Virol. 49:1984;102-108.
4. Douglas G. C., King B. F. Isolation of pure villous cytotrophoblast from term human placenta using immunomagnetic microspheres. J. Immunol. Methods. 119:1989;259-268.
5. Enders A. C. Trophoblast differentiation during the transition from trophoblast plate to lacunar stage of implantation in the rhesus monkey and human. Am. J. Anat. 186:1989;85-92.
6. Felgner P. L., Gadek T. R., Holm M., Roman R., Chan H. W., Wenz M., Northrop J. P., Ringold G. M., Danielsen M. Lipofectin: A highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA. 84:1987;7413-7417.
7. Goldstein J., Braverman M., Salafia C., Buckley P. The phenotype of human placental macrophages and its variation with gestational age. Am. J. Pathol. 133:1988;648-659.
8. 131. Biochem. J. 89:1963;114-123.
9. Hammarskjöld M. L., Simurda M. C. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J. Virol. 66:1992;6496-6501.
10. Hammerschmidt W., Sugden B. Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell. 55:1988;427-433.
11. Henderson E., Miller G., Robinson J., Heston L. Efficiency of transformation of lymphocytes by Epstein-Barr virus. Virology. 76:1977;152-163.
12. Henderson E. E., Yang J. Y., Zhang R. D., Bealer M. Altered HIV expression and EBV-induced transformation in coinfected PBLs and PBL subpopulations. Virology. 182:1991;186-198.
13. Henle W., Henle G., Zajac B. A., Pearson G., Waubke R., Scriba M. Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science. 169:1970;188-190.
14. Hinuma Y., Konn M., Yamaguchi J., Wudarski D. J., Blakeslee J. R., Grace J. T. Immunofluorescence and herpes type virus particles in the P3HR-1 Burkitt lymphoma cell line. J. Virol. 1:1967;1045-1051.
15. Hoffman A. D., Banapour B., Levy J. A. Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology. 147:1985;326-335.
16. Hoffman G. J., Sondra G. L., Hayward S. D. Monoclonal against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc. Natl. Acad. Sci. USA. 77:1980;2979-2983.
17. Holley-Guthrie E. A., Quinlivan E. B., Mar E. C., Kenney S. The Epstein-Barr (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J. Virol. 64:1990;3753-3759.
18. Hoxie J. A., Matthews D. M., Cines D. B. Infection of human endothelial cells by human T-cell leukemia virus type I. Proc. Natl. Acad. Sci. USA. 81:1984;7591-7595.
19. Huang E. S., Layrita M., Menezes J., Joncas J. H. Persistence of both human cytomegalovirus and Epstein-Barr virus genomes in two human lymphoblastoid cell lines. J. Gen. Virol. 40:1978;519-529.
20. Jeang K. T., Widen S. G., Semmes O. J., Wilson S. H. HTLV-I transactivator protein Tax, is a trans-repressor of the human polymerase gene. Science. 247:1990;1082-1084.
21. Joncas J. H., Alfieri C., Leyritz-Wills M., Brochu P., Jasmin G., Boldogh I., Huang E. S. Simultaneous congenital infection with Epstein-Barr virus and cytomegalovirus. N. Engl. J. Med. 304:1981;1399-1403.
22. Kalyaranaman V. S., Sarngadharan M. G., Poiesz B., Ruscetti F. W., Gallo R. C. Immunological properties of a type C retrovirus isolated from cultured human T-lymphoma cells and comparison to other mammalian retroviruses. J. Virol. 38:1981;906-915.
23. Katz S. L., Wilfert C. M. Human immunodeficiency virus infection of newborns. N. Engl. J. Med. 320:1989;1687-1689.
24. King W., Dambaugh T., Heller M., Dowling J., Kieff E. Epstein-Barr virus DNA. XII. A variable region of the Epstein-Barr virus genome is included in the P3HR-1 deletion. J. Virol. 43:1982;979-986.
25. Kinoshita K., Amagasaki T., Hino S., Doi M., Yamanouchi K., Ban N., Momita S., Ikeda S., Kanuhara S., Ichimaru M., Kitamine S., Miyamoto T., Tsuji Y., Ishimaru T., Yamabe T., Ito M., Kamura I., Tsuda T. Milk-born transmission of HTLV-I from carrier mothers to their children. Jpn. J. Cancer Res. 78:1987;674-680.
26. Klein G., Giovanelli B., Westman A., Stehlin J. S., Mumford D. An EBV-negative cell line established from an American Burkitt lymphoma; receptor characteristics, EBV-infectability and permanent conversion into EBV positive sublines by in vitro infection. Intervirology. 5:1975;319-334.
27. Koralnik I. J., Lemp J. F., Gallo R. C., Franchini G. In vitro infection of human macrophages by human T-cell leukemia/lymphotropic virus type I (HTLV-I). AIDS Res. Hum. Retroviruses. 8:1992;1845-1849.
28. Lemon I. M., Hutt L. M., Shaw J. E., Li J. L., Pagano J. S. Replication of EBV in epithelial cells during infectious mononucleosis. Nature. 268:1977;268-270.
29. Li J. S., Zhou B. S., Dutschman G. E., Grill S. P., Tan R. S., Chen Y. C. Association of Epstein-Barr virus early antigen diffuse component and virus-specific DNA polymerase activity. J. Virol. 61:1987;2947-2949.
30. Lieberman P. M., Berk A. J. The Zta transactivator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction. Genes Dev. 5:1991;2441-2454.
31. Lieberman P. M., Hardwick J. M., Sample J., Hayward G. S., Hayward S. D. The Zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter an enhancer regions. J. Virol. 64:1990;1143-1155.
32. Liu C., Sista N. D., Pagano J. S. Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and EZF. J. Virol. 70:1996.
33. Liu X., Zachar V., Nörskov-Lauritsen N., Aboagye-Mathiesen G., Zdravkovic M., Mosborg-Petersen P., Dalsgaard A. M., Hager H., Ebbesen P. Cell-mediated transmission of human T cell lymphotropic virus type I to human trophoblastic cells results in long-term persistent infection. J. Gen. Virol. 76:1995;167-173.
34. Lowell C. A., Klickstein L. B., Carter R. H., Mitchell J. A., Fearon D. T., Ahearn J. M. Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J. Exp. Med. 170:1989;1931-1937.
35. Lu Y., Stenzel M., Sodroski J. G., Haseltine W. A. Effects of long terminal repeat mutations on human immunodeficiency virus type 1 replication. J. Virol. 63:1989;4115-4119.
36. Mallon R., Borkowski J., Albin R., Pepitoni S., Schwartz J., Kieff E. The Epstein-Barr virus BZLF1 gene product activates the human immunodeficiency virus type 1 5′ long terminal repeat. J. Virol. 64:1990;6282-6285.
37. Mano H., Chermann J.-C. Fetal human immunodeficiency virus type 1 infection of different organs in the second trimester. AIDS Res. Hum. Retroviruses. 7:1991;83-88.
38. Marschall M., Leser U., Seibl R., Wolf H. Identification of proteins encoded by Epstein-Barr virus trans-activator genes. J. Virol. 63:1989;938-942.
39. McAllister R. M., Gardner M. B., Greene A. E., Bradt C., Nichols W. W., Landing B. H. Cultivation in vitro of cells derived from a human osteosarcoma. Cancer. 27:1971;397-402.
40. Miller G. Epstein-Barr Virus, Biology, Pathogenesis and Medical Aspects. 1990;Raven Press, New York. p. 1921-1958.
41. Miller G., Shope T., Lisco H., Stitt D., Lipman M. Epstein-Barr virus: Transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc. Natl. Acad. Sci. USA. 69:1972;383-387.
42. Mitchell M. D., Trautman M. S., Dudley D. J. Cytokine networking in the placenta. Placenta. 14:1993;249-275.
43. Miyoshi I., Kubonishi I., Yoshimoto S., Akagi T., Ohtsuki Y., Shiraishi Y., Nagata K., Hinuma Y. Type C virus particles in a cord blood T-cell line derived by co-cultivating normal human cord leukocytes and human leukemic T cells. Nature. 294:1981;770-771.
44. Nakano I., Ando Y., Saito K., Moriyama I., Ichijo M., Toyama T., Sugamura K., Imai J., Hinuma Y. Primary infection of Japanese infants with adult T-cell leukemia associated retrovirus: Evidence for viral transmission from mothers to children. J. Infect. 12:1986;205-212.
45. Nara P. L., Hatch W. C., Dunlop N. M., Robey W. G., Arthur L. O., Gonda M. A., Fischinger P. J. Simple, rapid, quantitative, syncytiumforming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res. Hum. Retroviruses. 3:1987;283-302.
46. New R. R. C., Black C. D. V., Parker R. J., Puri A., Scherphof G. L. Liposomes in biological systems. New R. R. C. Liposomes: A Practical Approach. 1990;243-251 IRL Press, Oxford.
47. Pizzo P. A., Magrath I. T., Chattopadhyay S. K., Biggar R. J., Gerber P. A new tumour-derived transforming strain of Epstein-Barr virus. Nature. 272:1978;629-631.
48. Pulvertaft R. J. V. Cytology of Burkitt's tumour (African lymphoma). Lancet. I:1964;238-240.
49. Pulvertaft R. J. V. A study of malignant tumours in Nigeria by short term tissue culture. J. Clin. Pathol. 18:1965;261-273.
50. Quinlivan E. B., Holley-Guthrie E., Mar E. C., Smith M. S., Kenney S. The Epstein-Barr virus BRLF1 immediate-early gene product transactivates the human immunodeficiency virus type 1 long terminal repeat by a mechanism which is enhancer independent. J. Virol. 64:1990;1817-1820.
51. Rho H. M., Poiesz B., Ruscetti F. W., Gallo R. C. Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology. 112:1981;355-360.
52. Rubinstein A. Pediatric AIDS. Curr. Probl. Pediatr. 16:1986;365-409.
53. Saito I., Servenius B., Compton T., Fox R. I. Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjögren's syndrome. J. Exp. Med. 169:1989;2191-2198.
54. Saito S., Furuki K., Ando Y., Tanigawa T., Kakimoto K., Moriyama I., Ichijo M. Identification of HTLV-I sequence in cord blood mononuclear cells of neonates born to HTLV-I antigen/antibody-positive mothers by polymerase chain reaction. Jpn. J. Cancer Res. 81:1990;890-895.
55. Salahuddin S. Z., Ablashi D. V., Hunter E. A., Gonda M. A., Sturzenegger S., Markham P. D., Gallo R. C. HTLV-III infection of EBV-genome-positive B-lymphoid cells with or without detectable T4 antigens. Int. J. Cancer. 39:1987;198-202.
56. Satow Y., Hashido M., Ishikawa K., Honda H., Mizuno M., Kawana T., Kayami M. Detection of HTLV-I antigen in peripheral and cord blood lymphocytes from carrier mothers. Lancet. 338:1991;915-916.
57. Scala G., Quinto I., Ruocco M. R., Mallardo M., Ambrosino C., Squitieri B., Tassone P., Venuta S. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1. J. Virol. 67:1993;2853-2861.
58. Sculley T. B., Apolloni A., Hurren L., Moss D. J., Cooper D. A. Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J. Infect. Dis. 162:1990;643-648.
59. Sixbey J. W., Davis D. S., Young L. S., Hutt-Fletcher L., Tedder T. T., Rickinson A. B. Human epithelial cell expression of an Epstein-Barr virus receptor. J. Gen. Virol. 68:1987;805-811.
60. Sixbey J. W., Shirley P., Sloas M., Raab-Traub N., Israele V. A transformation-incompetent, nuclear antigen 2-deleted Estein-Barr virus associated with replicative infection. J. Infect. Dis. 163:1991;1008-1015.
61. Takada K. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int. J. Cancer. 33:1984;27-32.
62. Thiry L., Sprecher-Goldberger S., Jonckheer T., Levy J., Cogniaux-Leclerc J., Clumek N. Isolation of AIDS virus from cell free breast milk of three healthy virus carriers. Lancet. II:1985;891-892.
63. Thorley-Lawson D. A., Edson C. M. Polypeptides of the Epstein-Barr virus membrane antigen complex. J. Virol. 32:1979;458-467.
64. Thorley-Lawson D. A., Poodry C. A. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J. Virol. 43:1982;730-736.
65. Tokunaga M., Imai S., Uemura Y., Tokudome T., Osato T., Sato E. Epstein-Barr virus in adult T-cell leukemia/lymphoma. Am. J. Pathol. 143:1993;1263-1269.
66. Tóth F. D., Mosborg-Petersen P., Kiss J., Aboagye-Mathiesen G., Hager H., Juhl C. B., Gergely L., Zdravkovic M., Aranyosi J., Lampé L., Ebbesen P. Interactions between human immunodeficiency virus type 1 and human cytomegalovirus in human term syncytiotrophoblast cells coinfected with both viruses. J. Virol. 69:1995a;2223-2232.
67. Tóth F. D., Aboagye-Mathiesen G., Szabó J., Liu X., Mosborg-Petersen P., Kiss J., Hager H., Zdravkovic M., Andirkó I., Aranyosi J., Ebbesen P. Bidirectional enhancing activities between human T cell leukemia-lymphoma virus type I and human cytomegalovirus in human term syncytiotrophoblast cells cultured in vitro. AIDS Res. Hum. Retroviruses. 11:1995b;1495-1507.
68. Van Kuyk R., Mosier D. E. Lack of pseudotype formation between human immunodeficiency virus type 1 and Epstein-Barr virus in productively coinfected B lymphoblastoid cell lines. Virology. 209:1995;643-648.
69. Wong K. M., Levine A. J. Characterization of proteins encoded by the Epstein-Barr virus transactivator gene BMLF1. Virology. 168:1989;101-111.
70. Yamamoto N., Matsumoto T., Koyanagi Y., Tanaka Y., Hinuma Y. Unique cell lines harbouring both Epstein-Barr virus and adult T-cell leukaemia virus, established from leukaemia patients. Nature. 299:1982;367-369.
71. Zachar V., Nörskov-Lauritsen N., Juhl C., Spire B., Chermann J.-C., Ebbesen P. Susceptibility of cultured human trophoblasts to infection with human immunodeficiency virus type 1. J. Gen. Virol. 72:1991;1253-1260.
72. Ziegler J. B., Cooper D. A., Johnson R. O., Gold J. Postnatal transmission of AIDS-associated retrovirus from mother to infant. Lancet. I:1985;896-898.
73. Zimber-Strobl U., Adldinger H. K., Lenoir G. M., Vuillaume M., von Knebel-Doeberitz M., Laux G., Desgranges C., Wittman P., Freese U. K., Schneider U., Bornkamm G. W. Geographical prevalence of two Epstein-Barr virus types. Virology. 154:1986;56-66.
74. Zur Hausen H., O'Neill F. J., Freese U. K., Hecker E. Persisting oncogenic herpesvirus induced by the tumor promoter TPA. Nature. 272:1978;373-375.